Last reviewed · How we verify
OKITASK®
OKITASK is a topical ophthalmic agent designed to promote corneal healing and reduce inflammation in dry eye disease.
OKITASK is a topical ophthalmic agent designed to promote corneal healing and reduce inflammation in dry eye disease. Used for Dry eye disease (moderate to severe).
At a glance
| Generic name | OKITASK® |
|---|---|
| Also known as | ketoprofen lysine salt (KLS) |
| Sponsor | Dompé Farmaceutici S.p.A |
| Drug class | Ophthalmic anti-inflammatory/corneal healing agent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
The drug works through a mechanism that supports corneal epithelial regeneration and reduces ocular surface inflammation associated with dry eye syndrome. It is intended to improve tear film stability and promote healing of damaged corneal tissue in patients with moderate to severe dry eye disease.
Approved indications
- Dry eye disease (moderate to severe)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OKITASK® CI brief — competitive landscape report
- OKITASK® updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI